Byrne discusses Dova's recent Late Breaker at the United European Gastroenterology (UEG) Week 2025, where AI re-analysis uncovered treatment effects missed by human readers. He explains how AI may soon become integral to clinical trial design, regulatory review, and drug approval, while predicting how AI-human partnerships will define the future of gastroenterology.

Timestamps:
01:05 – AI in the TITRATE trial
03:18 – Validating clinical endpoints
04:16 – AI and human readers
16:53 – The next frontier in gastrointestinal AI

Bias, privacy, and ethics take centre stage as Byrne discusses how to build trustworthy AI systems. From data transparency to global access, he shares practical steps to ensure equitable innovation and reflects on the fears clinicians express about integrating AI in their daily workflow.

Timestamps:
01:09 – Addressing bias and inequity
03:10 – Data privacy and regulation
04:40 – Trust and clinical accountability
06:52 – Educating clinicians on AI use

In this first deep dive, Byrne explores how AI is revolutionising inflammatory bowel disease care. He discusses the DovaVision™ UC (Dova Health Intelligence, Vancouver, Canada) Mayo Endoscopic Score developed with the Mayo Clinic; the power of multimodal AI in combining colonoscopy, ultrasound, and lab data; and how AI reduces interobserver variability in disease scoring.

Timestamps:
01:04 – The landscape of AI in inflammatory bowel disease
02:54 – DovaVision™ UC (Dova Health Intelligence, Vancouver, Canada) Mayo collaboration
04:26 – Colonoscopy and AI
08:30 – The future of multimodal AI